Therapeutic Areas

The primary goal of drugs targeting tumor metabolism pathways is to take advantage of cancer-specific nutrient dependencies to block cancer growth or activate the body’s cancer-fighting cells.

Changes in cellular metabolism are remarkably consistent across many tumor types, yet fundamentally different from normal cells, providing the potential to develop broadly applicable agents that target these altered pathways, but have less toxicity than standard cytotoxic agents.

Our primary focus is in renal cell carcinoma, where we are evaluating telaglenastat in two randomized Phase 2 trials. ENTRATA is a randomized, double-blind, Phase 2 study comparing telaglenastat in combination with everolimus vs. placebo with everolimus in patients with advanced renal cell carcinoma. CANTATA is a global, randomized, double-blind Phase 2 study comparing telaglenastat in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced or metastatic renal cell carcinoma. Telaglenastat is also being evaluated in multiple combination trials. In addition to these company sponsored clinical trials, telaglenastat is also being studied in investigator-sponsored trials.

Renal Cell Carcinoma (RCC)

According to the National Cancer Institute, renal cell carcinoma is diagnosed in approximately 62,700 people each year in the United States. RCC is the most common type of kidney cancer. Approximately 50% of renal cell carcinoma patients will require chemotherapy at some point to treat their metastatic disease. Clear cell is the most common form of kidney cancer comprising 75%-85% of cases.